Lisata Therapeutics Inc (LSTA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.65+0.61%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LSTA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -31.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
LSTA — President transition
Dated 2026-08-04
Executive Vice President of R&D and Chief Medical Officer — Dr. Kristen K. Buck, M.D.: The employment of Dr. Kristen K. Buck was terminated as part of a workforce reduction.
Why it matters: Completing the merger is key for Lisata's growth. Delays may show ongoing problems.
Supportive ifThe merger is completed and announced by both companies.
Worry ifMore delays or ending the merger agreement.
Why it matters: Better financial results would show cost cuts are working and problems are lessening.
Supportive ifNet losses drop a lot compared to past quarters.
Worry ifNet losses remain high or worsen in the next financial report.
Why it matters: Looking at strategic options could help Lisata find new chances.
Supportive ifA news release about a partnership, merger, or sale happens.
Worry ifNo updates or news on strategic options are shared.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$227 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $709 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,036 loss on $10,000 · 80.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.